Jane Gartlon

1.3k total citations
18 papers, 628 citations indexed

About

Jane Gartlon is a scholar working on Cellular and Molecular Neuroscience, Molecular Biology and Pharmacology. According to data from OpenAlex, Jane Gartlon has authored 18 papers receiving a total of 628 indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Cellular and Molecular Neuroscience, 8 papers in Molecular Biology and 4 papers in Pharmacology. Recurrent topics in Jane Gartlon's work include Neuroscience and Neuropharmacology Research (9 papers), Receptor Mechanisms and Signaling (6 papers) and Alzheimer's disease research and treatments (4 papers). Jane Gartlon is often cited by papers focused on Neuroscience and Neuropharmacology Research (9 papers), Receptor Mechanisms and Signaling (6 papers) and Alzheimer's disease research and treatments (4 papers). Jane Gartlon collaborates with scholars based in United Kingdom, United States and Japan. Jane Gartlon's co-authors include Declan N.C. Jones, Lee A. Dawson, Laura W. Harris, Trevor Sharp, Paul J. Harrison, Marie L. Woolley, Jeanette Watson, Jim J. Hagan, Matthew Barron and Eric Southam and has published in prestigious journals such as Brain Research, British Journal of Pharmacology and Frontiers in Immunology.

In The Last Decade

Jane Gartlon

18 papers receiving 616 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Jane Gartlon United Kingdom 13 306 243 128 101 84 18 628
Ilga Misane Sweden 17 622 2.0× 394 1.6× 286 2.2× 78 0.8× 104 1.2× 21 945
Serena Stopponi Italy 20 623 2.0× 344 1.4× 190 1.5× 203 2.0× 144 1.7× 26 930
Katalin Szebeni United States 16 300 1.0× 188 0.8× 120 0.9× 120 1.2× 69 0.8× 24 798
Holden D. Brown United States 8 272 0.9× 206 0.8× 169 1.3× 81 0.8× 42 0.5× 10 611
Roger Raymond Canada 17 569 1.9× 256 1.1× 245 1.9× 108 1.1× 61 0.7× 46 994
Raúl Martín‐Ruiz Spain 12 577 1.9× 267 1.1× 128 1.0× 198 2.0× 35 0.4× 13 851
Belén Gago Spain 21 654 2.1× 439 1.8× 105 0.8× 54 0.5× 42 0.5× 47 1.1k
Laure Seguin France 14 364 1.2× 235 1.0× 66 0.5× 67 0.7× 112 1.3× 24 660
Yun Tan China 13 342 1.1× 183 0.8× 198 1.5× 53 0.5× 54 0.6× 22 923
Olivier Bergis France 14 432 1.4× 408 1.7× 137 1.1× 185 1.8× 19 0.2× 19 788

Countries citing papers authored by Jane Gartlon

Since Specialization
Citations

This map shows the geographic impact of Jane Gartlon's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jane Gartlon with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jane Gartlon more than expected).

Fields of papers citing papers by Jane Gartlon

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jane Gartlon. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jane Gartlon. The network helps show where Jane Gartlon may publish in the future.

Co-authorship network of co-authors of Jane Gartlon

This figure shows the co-authorship network connecting the top 25 collaborators of Jane Gartlon. A scholar is included among the top collaborators of Jane Gartlon based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jane Gartlon. Jane Gartlon is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

18 of 18 papers shown
1.
Talma, Sonia, Jane Gartlon, Eri Takahashi, et al.. (2023). Efficacy of the murine version of E2814 in a validated AD brain seed‐injection model in hTau mice. Alzheimer s & Dementia. 19(S21). 2 indexed citations
2.
Barron, Matthew, Jane Gartlon, Lee A. Dawson, Peter J. Atkinson, & Marie‐Christine Pardon. (2020). Increasing Tau 4R Tau Levels Exacerbates Hippocampal Tau Hyperphosphorylation in the hTau Model of Tauopathy but Also Tau Dephosphorylation Following Acute Systemic Inflammation. Frontiers in Immunology. 11. 293–293. 13 indexed citations
3.
Roberts, Malcolm C., Ioanna Sevastou, Yoichi Imaizumi, et al.. (2019). P4‐695: E2814: A NOVEL ANTI‐TAU THERAPEUTIC ANTIBODY FOR ALZHEIMER'S DISEASE. Alzheimer s & Dementia. 15(7S_Part_31). 1 indexed citations
4.
Barron, Matthew, Jane Gartlon, Lee A. Dawson, Peter J. Atkinson, & Marie‐Christine Pardon. (2016). A state of delirium: Deciphering the effect of inflammation on tau pathology in Alzheimer's disease. Experimental Gerontology. 94. 103–107. 52 indexed citations
5.
6.
Madin, Andrew, Desmond O’Connor, Tohru Arai, et al.. (2015). Identification and optimisation of a series of tetrahydrobenzotriazoles as metabotropic glutamate receptor 5-selective positive allosteric modulators that improve performance in a preclinical model of cognition. Bioorganic & Medicinal Chemistry Letters. 25(24). 5792–5796. 6 indexed citations
7.
Forbes, Ian T., Steve P. Watson, Graeme I. Stevenson, et al.. (2010). The discovery of a series of N-substituted 3-(4-piperidinyl)-1,3-benzoxazolinones and oxindoles as highly brain penetrant, selective muscarinic M1 agonists. Bioorganic & Medicinal Chemistry Letters. 20(18). 5434–5438. 16 indexed citations
8.
Southam, Eric, Jackie Cilia, Jane Gartlon, et al.. (2008). Preclinical investigations into the antipsychotic potential of the novel histamine H3 receptor antagonist GSK207040. Psychopharmacology. 201(4). 483–494. 44 indexed citations
9.
10.
Woolley, Marie L., Kerry A. Waters, Jane Gartlon, et al.. (2008). Evaluation of the pro-cognitive effects of the AMPA receptor positive modulator, 5-(1-piperidinylcarbonyl)-2,1,3-benzoxadiazole (CX691), in the rat. Psychopharmacology. 202(1-3). 343–354. 41 indexed citations
11.
Dawson, Lee A., Claire M. Scott, Jeannette M. Watson, et al.. (2007). In Vitro and In Vivo Characterization of the Non-peptide NK3 Receptor Antagonist SB-223412 (Talnetant): Potential Therapeutic Utility in the Treatment of Schizophrenia. Neuropsychopharmacology. 33(7). 1642–1652. 34 indexed citations
12.
Southam, Eric, Carol A. Jennings, Jane E. Cluderay, et al.. (2007). Effect of the selective dopamine D3 receptor antagonist SB-277011-A on regional c-Fos-like expression in rat forebrain. Brain Research. 1149. 50–57. 15 indexed citations
13.
Jennings, C.A., Jane E. Cluderay, Jane Gartlon, et al.. (2005). The effects of ziprasidone on regional c-Fos expression in the rat forebrain. Psychopharmacology. 184(1). 13–20. 12 indexed citations
14.
Gartlon, Jane, Tracey Ashmeade, Mark Duxon, Jim J. Hagan, & Declan N.C. Jones. (2004). Urotensin-II, a neuropeptide ligand for GPR14, induces c-fos in the rat brain. European Journal of Pharmacology. 493(1-3). 95–98. 7 indexed citations
15.
Harris, Laura W., Trevor Sharp, Jane Gartlon, Declan N.C. Jones, & Paul J. Harrison. (2003). Long‐term behavioural, molecular and morphological effects of neonatal NMDA receptor antagonism. European Journal of Neuroscience. 18(6). 1706–1710. 139 indexed citations
16.
Southam, Eric, C.A. Jennings, Jane E. Cluderay, et al.. (2003). Effect of the selective dopamine D3 receptor antagonist SB-277011 on regional fos expression in the rat forebrain. Schizophrenia Research. 60(1). 316–316. 3 indexed citations
17.
Jones, Declan N.C., Jane Gartlon, Frederick B. Parker, et al.. (2001). Effects of centrally administered orexin-B and orexin-A: a role for orexin-1 receptors in orexin-B-induced hyperactivity. Psychopharmacology. 153(2). 210–218. 78 indexed citations
18.
Gartlon, Jane, Frederick B. Parker, David C. Harrison, et al.. (2001). Central effects of urotensin-II following ICV administration in rats. Psychopharmacology. 155(4). 426–433. 69 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Ilga Misane Breakdown of academic impact, for papers by Serena Stopponi Breakdown of academic impact, for papers by Katalin Szebeni Breakdown of academic impact, for papers by Holden D. Brown Breakdown of academic impact, for papers by Roger Raymond Breakdown of academic impact, for papers by Raúl Martín‐Ruiz Breakdown of academic impact, for papers by Belén Gago Breakdown of academic impact, for papers by Laure Seguin Breakdown of academic impact, for papers by Yun Tan Breakdown of academic impact, for papers by Olivier Bergis
Rankless by CCL
2026